These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2005-001781-14 A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN (IMVAMUNE™) smallpox vaccine in 1... 2007-08-27 due-trials
Reported results 2007-006297-28 An open-label Phase II study to evaluate immunogenicity and safety of a single IMVAMUNE® booster vaccination two years after the last IMVAMUNE® vaccination in former POX-MVA-005 vaccinees 2009-07-09 due-trials
Completed, but no date Terminated 2010-018334-51 An open-label, non-controlled study to immunize healthy volunteers actively working with or in the vicinity of replicating Vaccinia virus with IMVAMUNE® (MVA-BN®) bad-data
Reported results 2010-021196-85 A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer 2017-10-02 due-trials
Ongoing 2012-005137-37 Open-label, non-controlled, multicenter immunogenicity and safety study of MVA-BN® smallpox vaccine in children from birth to less than 12 years of age Offene, nicht kontrollierte, multizentrische... not-yet-due
Not reported 2017-004582-27 A Phase 2a Randomized, Double-blinded, Placebo-controlled Trial to assess the Safety, Immunogenicity, and Efficacy of the recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection i... 2019-09-30 due-trials
Ongoing 2021-001393-31 An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects. Offene Phase 2 Studie zur Best... not-yet-due
Ongoing 2021-004923-34 A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN®-RSV Vaccine in Adults ≥60 Years of Age Randomisierte, doppel-blinde Pha... not-yet-due
Ongoing 2021-005504-36 Covid-19: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized... not-yet-due